1
|
Venditti A, Piciocchi A, Candoni A, Arena V, Palmieri R, Filì C, Carella AM, Calafiore V, Cairoli R, de Fabritiis P, Storti G, Salutari P, Lanza F, Martinelli G, Curti A, Luppi M, Ingrosso C, Martelli MP, Cuneo A, Albano F, Mulè A, Tafuri A, Cudillo L, Tieghi A, Fracchiolla NS, Capelli D, Trisolini SM, Alati C, La Sala E, Maurillo L, Del Principe MI, Irno Consalvo MA, Divona MD, Ottone T, Cerretti R, Sconocchia G, Voso MT, Fazi P, Vignetti M, Buccisano F. Risk-adapted MRD-directed therapy for young adults with acute myeloid leukemia: 6-year update of the GIMEMA AML1310 trial. Blood Adv 2024; 8:4410-4413. [PMID: 38968139 PMCID: PMC11375254 DOI: 10.1182/bloodadvances.2024013182] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2024] [Revised: 06/18/2024] [Accepted: 06/18/2024] [Indexed: 07/07/2024] Open
Affiliation(s)
- Adriano Venditti
- Hematology, Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy
- Fondazione Policlinico Tor Vergata, Rome, Italy
| | | | - Anna Candoni
- Clinica Ematologica, Azienda Ospedaliero-Universitaria "Santa Maria della Misericordia" di Udine, Italy
- Ematologia, Dipartimento di Scienze Mediche e Chirurgiche Materno-Infantili e dell'Adulto, Università degli Studi di Modena e Reggio Emilia, Modena, Italy
| | | | - Raffaele Palmieri
- Hematology, Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy
| | - Carla Filì
- Clinica Ematologica, Azienda Ospedaliero-Universitaria "Santa Maria della Misericordia" di Udine, Italy
| | - Angelo Michele Carella
- Fondazione IRCCS Casa Sollievo della Sofferenza, UO di Ematologia, San Giovanni Rotondo, Italy
| | | | - Roberto Cairoli
- ASST Grande Ospedale Metropolitano Niguarda-Milano; Università degli Studi di Milano-Bicocca, Milan, Italy
| | - Paolo de Fabritiis
- Hematology, S.Eugenio Hospital, ASL Roma 2, University Tor Vergata, Rome, Italy
| | | | | | | | - Giovanni Martinelli
- IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori," Meldola, Italy
| | - Antonio Curti
- IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli," Bologna, Italy
| | - Mario Luppi
- Ematologia, Dipartimento di Scienze Mediche e Chirurgiche Materno-Infantili e dell'Adulto, Università degli Studi di Modena e Reggio Emilia, Modena, Italy
| | | | | | - Antonio Cuneo
- Azienda Ospedaliero-Universitaria Arcispedale Sant'Anna, Ferrara, Italy
| | - Francesco Albano
- Hematology and Stem Cell Transplantation Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari "Aldo Moro," Bari, Italy
| | - Antonino Mulè
- Ospedali Riuniti Villa Sofia-Cervello, Palermo, Italy
| | - Agostino Tafuri
- Ematologia, Azienda Ospedaliera Universitaria Sant' Andrea-Sapienza, Dipartimento di Medicina Clinica e Molecolare, Rome, Italy
| | - Laura Cudillo
- UOC Ematologia, Azienda Ospedaliera S.Giovanni Addolorata, Rome, Italy
| | | | | | - Debora Capelli
- Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona, Ancona, Italy
| | - Silvia Maria Trisolini
- Haematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy
| | - Caterina Alati
- UOC Ematologia GOM Bianchi Melacrino Morelli, Reggio Calabria, Italy
| | | | | | - Maria Ilaria Del Principe
- Hematology, Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy
- Fondazione Policlinico Tor Vergata, Rome, Italy
| | | | | | - Tiziana Ottone
- Hematology, Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy
| | | | - Giuseppe Sconocchia
- Institute of Translational Pharmacology, National Research Council, Rome, Italy
| | - Maria Teresa Voso
- Hematology, Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy
- Fondazione Policlinico Tor Vergata, Rome, Italy
| | | | | | - Francesco Buccisano
- Hematology, Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy
- Fondazione Policlinico Tor Vergata, Rome, Italy
| |
Collapse
|
2
|
Piciocchi A, Cipriani M, Messina M, Marconi G, Arena V, Soddu S, Crea E, Feraco MV, Ferrante M, La Sala E, Fazi P, Buccisano F, Voso MT, Martinelli G, Venditti A, Vignetti M. Unlocking the potential of synthetic patients for accelerating clinical trials: Results of the first GIMEMA experience on acute myeloid leukemia patients. EJHAEM 2024; 5:353-359. [PMID: 38633115 PMCID: PMC11020105 DOI: 10.1002/jha2.873] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/12/2024] [Accepted: 02/13/2024] [Indexed: 04/19/2024]
Abstract
Artificial Intelligence has the potential to reshape the landscape of clinical trials through innovative applications, with a notable advancement being the emergence of synthetic patient generation. This process involves simulating cohorts of virtual patients that can either replace or supplement real individuals within trial settings. By leveraging synthetic patients, it becomes possible to eliminate the need for obtaining patient consent and creating control groups that mimic patients in active treatment arms. This method not only streamlines trial processes, reducing time and costs but also fortifies the protection of sensitive participant data. Furthermore, integrating synthetic patients amplifies trial efficiency by expanding the sample size. These straightforward and cost-effective methods also enable the development of personalized subject-specific models, enabling predictions of patient responses to interventions. Synthetic data holds great promise for generating real-world evidence in clinical trials while upholding rigorous confidentiality standards throughout the process. Therefore, this study aims to demonstrate the applicability and performance of these methods in the context of onco-hematological research, breaking through the theoretical and practical barriers associated with the implementation of artificial intelligence in medical trials.
Collapse
Affiliation(s)
| | - Marta Cipriani
- Data CenterGIMEMA FoundationRomeItaly
- Department of Statistical SciencesUniversity of Rome La SapienzaRomeItaly
| | | | - Giovanni Marconi
- Hematology UnitIRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”MeldolaItaly
| | | | | | | | | | - Marco Ferrante
- Department Health Care and Life SciencesStudio Legale FLCRomeItaly
| | | | | | | | - Maria Teresa Voso
- Department of Biomedicine and PreventionTor Vergata UniversityRomeItaly
| | - Giovanni Martinelli
- Hematology UnitIRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”MeldolaItaly
| | - Adriano Venditti
- Department of Biomedicine and PreventionTor Vergata UniversityRomeItaly
| | | |
Collapse
|
3
|
A Focus on Intermediate-Risk Acute Myeloid Leukemia: Sub-Classification Updates and Therapeutic Challenges. Cancers (Basel) 2022; 14:cancers14174166. [PMID: 36077703 PMCID: PMC9454629 DOI: 10.3390/cancers14174166] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2022] [Revised: 08/16/2022] [Accepted: 08/25/2022] [Indexed: 11/16/2022] Open
Abstract
Acute myeloid leukemia (AML) represents a heterogeneous group of hematopoietic neoplasms deriving from the abnormal proliferation of myeloid progenitors in the bone marrow. Patients with AML may have highly variable outcomes, which are generally dictated by individual clinical and genomic characteristics. As such, the European LeukemiaNet 2017 and 2022 guidelines categorize newly diagnosed AML into favorable-, intermediate-, and adverse-risk groups, based on their molecular and cytogenetic profiles. Nevertheless, the intermediate-risk category remains poorly defined, as many patients fall into this group as a result of their exclusion from the other two. Moreover, further genomic data with potential prognostic and therapeutic influences continue to emerge, though they are yet to be integrated into the diagnostic and prognostic models of AML. This review highlights the latest therapeutic advances and challenges that warrant refining the prognostic classification of intermediate-risk AML.
Collapse
|